This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Acquisition Of Cadence Pharmaceuticals, Inc. By Mallinckrodt Plc May Not Be In Shareholders' Best Interests

Stocks in this article: CADX MNK

SAN DIEGO, Feb. 11, 2014 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Cadence Pharmaceuticals, Inc. (NASDAQ: CADX) by Mallinckrodt plc (NYSE: MNK).  On February 11, 2014, the two companies announced the signing of a definitive agreement pursuant to which a subsidiary of Mallinckrodt will commence a tender offer to acquire all outstanding shares of Cadence stock for $14.00 per share in cash.

(Logo: Is the Proposed Merger Best for Cadence and Its Shareholders?

Robbins Arroyo LLP's investigation focuses on whether the board of directors at Cadence is undertaking a fair process to obtain maximum value and adequately compensate Cadence shareholders.

As an initial matter, the $14.00 merger consideration represents a premium to shareholders of just 26.5% based on Cadence's closing price on February 10, 2014.  This one day premium is significantly below the average one day premium of over 36% for comparable transactions in the last three years. Further, the merger consideration is below the target price of $15.00 set by analysts at Guggenheim Securities, LLC and Wedbush, Inc. 

In addition, on November 5, 2013, Cadence released its financial results for the third quarter ended September 30, 2013, reporting impressive increases in net product revenue, gross margin on sales of OFIRMEV, and the number of unique end-user customer accounts that ordered OFIRMEV.  Specifically, Cadence reported that its net product revenue increased 109%, or $15.1 million, over the comparable quarter 2012.  Cadence further reported that the number of unique end-user customer accounts that ordered OFIRMEV increased 33% for the quarter while the gross margin on sales of OFRIMEV rose to 66% compared with 56% for the same period in 2012. In commenting on the these results, Cadence's President and Chief Executive Officer, Ted Schroeder, remarked, "We maintained our strong performance during the third quarter, with OFIRMEV continuing to gain market share and posting year-over-year sales growth of more than 100% in each quarter of 2013." 

Given these facts, Robbins Arroyo LLP is examining the Cadence board of directors' decision to sell the company to Mallinckrodt now rather than allow shareholders to continue to participate in the company's continued success and future growth prospects. 

Cadence shareholders have the option to file a class action lawsuit to ensure the board of directors obtains the best possible price for shareholders and the disclosure of material information.  Cadence shareholders interested in information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003,, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The law firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.   

Attorney Advertising. Past results do not guarantee a similar outcome.  

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs